Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Drew_Fromkin
|
| gptkbp:developedBy |
targeted cancer therapies
|
| gptkbp:focus |
oncology
cancer therapeutics |
| gptkbp:formerName |
gptkb:Blend_Therapeutics
|
| gptkbp:founded |
2011
|
| gptkbp:headquarters_location |
gptkb:Watertown,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tarveda Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:investor |
gptkb:Polaris_Partners
gptkb:Flagship_Pioneering gptkb:NanoDimension gptkb:Novo_Holdings gptkb:New_Enterprise_Associates |
| gptkbp:product_candidate |
gptkb:PEN-221
gptkb:PEN-866 |
| gptkbp:servesArea |
gptkb:United_States
|
| gptkbp:specializesIn |
miniature drug conjugates
|
| gptkbp:website |
https://www.tarvedatx.com/
|
| gptkbp:bfsParent |
gptkb:GemRIS
|
| gptkbp:bfsLayer |
5
|